Gilead Sciences (NQ: GILD )

The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible.

Thoughts For Thursday: Risk-off, Risk-on

February 09, 2023

Via Talk Markets

NeurAxis: Should You Buy This IPO?

February 08, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

Via Talk Markets

Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030

February 08, 2023

Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...

Via SBWire

Topics Death

Exposures Death

Gilead Issues Unexpectedly Bullish Outlook After Cancer Drug Sales Rocket

February 02, 2023

The company posted another massive quarter for cancer treatment sales.

Via Investor's Business Daily

Mount Gilead, OH Author Publishes Children's Book

February 02, 2023

This Kids Book Features the Cutest Baby Elephant You Will Ever See!

Via PR Leap

Earnings Outlook For Gilead Sciences

February 01, 2023

Via Benzinga

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Via MarketBeat

Topics ETFs

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Via Talk Markets

Is Gilead Sciences a Good Stock to Buy Now?

February 06, 2023

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today

January 27, 2023

Via Benzinga

Could Gilead Sciences Stock Help You Become a Millionaire?

January 26, 2023

Does Gilead have enough growth potential to become a market-beating investment?

Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting

February 03, 2023

Via Benzinga

'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React

February 03, 2023

The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.

Via Benzinga

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

February 03, 2023

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

February 03, 2023

Gilead's strongest growth since 2015 comes with an asterisk.

GILD earnings call for the period ending December 31, 2022.

Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript

February 02, 2023

Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported

Why Gilead Sciences Stock Is Trading Higher After Hours

February 02, 2023

Via Benzinga

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

February 02, 2023

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

February 02, 2023

Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029

February 02, 2023

Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG

Via SBWire

Exposures COVID-19

Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?

February 02, 2023

The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging.

Via Benzinga

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

February 01, 2023

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts

January 31, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

January 30, 2023

From Gilead Sciences, Inc. and Arcellx, Inc.

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Gilead Sciences to Present at Upcoming Investor Conferences

January 27, 2023